![Charles Newton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Newton
Directeur/Bestuurslid bij
COHERUS ONCOLOGY, INC.
Vermogen: 733 169 $ op 31-05-2026
Profiel
Charles W.
Newton is currently an Independent Director at Coherus Oncology, Inc. since 2022, an Independent Director at Novavax, Inc. starting in 2025, and a Director at Keros Therapeutics, Inc. starting in 2026.
Former positions include Independent Director at 2seventy Bio, Inc. from 2024 to 2025, Managing Director at BofA Securities, Inc., Managing Director at Credit Suisse Group AG from 2010 to 2015, Independent Director at Carmot Therapeutics, Inc. from 2023 to 2024, MD & Head-Western Region Healthcare Investment at Morgan Stanley from 1996 to 2010, Chief Financial & Accounting Officer at Lyell Immunopharma, Inc. from 2021 to 2025, and MD & Head-Healthcare Investment Banking at Bank of America Corp.
from 2015 to 2021.
Education includes undergraduate studies at Miami University and an MBA from Tuck School of Business at Dartmouth.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-08-2025 | 25.306 ( 0,11% ) | 438 553 $ | 31-05-2026 | |
| 11-06-2026 | 12.665 ( 0,06% ) | 142 481 $ | 31-05-2026 | |
NOVAVAX, INC. 0,01% | 18-06-2026 | 9.520 ( 0,01% ) | 104 434 $ | 31-05-2026 |
| 05-06-2026 | 30.000 ( 0,02% ) | 47 700 $ | 31-05-2026 |
Actieve functies van Charles Newton
| Bedrijven | Functie | Begin |
|---|---|---|
| COHERUS ONCOLOGY, INC. | Directeur/Bestuurslid | 05-05-2022 |
| NOVAVAX, INC. | Directeur/Bestuurslid | 25-04-2025 |
| KEROS THERAPEUTICS, INC. | Directeur/Bestuurslid | 09-03-2026 |
Eerdere bekende functies van Charles Newton
| Bedrijven | Functie | Einde |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Financieel Directeur/CFO | 21-10-2025 |
| 2SEVENTY BIO, INC. | Directeur/Bestuurslid | 13-05-2025 |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Directeur/Bestuurslid | 01-01-2024 |
| BANK OF AMERICA CORPORATION | Corporate Officer/Principal | 01-02-2021 |
Credit Suisse Group AG /US/
 Credit Suisse Group AG /US/ Financial ConglomeratesFinance Provides financial services | Algemeen Directeur | 01-11-2015 |
Opleiding van Charles Newton
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
94
Eerstegraads connecties
12
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 12 |
|---|---|
Bank of America Corp.
 Bank of America Corp. Major BanksFinance Operates as a bank holding company whose subsidiaries provides consumer and global banking, markets brokerage & wealth and investment management services | Finance |
Morgan Stanley
 Morgan Stanley Investment ManagersFinance Provides wealth and asset management, trading & investment banking services | Finance |
Novavax, Inc.
 Novavax, Inc. BiotechnologyHealth Technology Engages in development of novel recombinant vaccines | Health Technology |
Miami University
 Miami University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Health Technology |
Tuck School of Business at Dartmouth
 Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coherus BioSciences, Inc.
 Coherus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial-stage biopharmaceutical company that engages in research, development and commercialization of immunotherapies to treat cancer | Health Technology |
Keros Therapeutics, Inc.
 Keros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for muscle diseases | Health Technology |
BofA Securities, Inc.
 BofA Securities, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Provides financial services | Finance |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
2seventy Bio, Inc.
 2seventy Bio, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for the treatment of cancer and genetic diseases | Health Technology |
